The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease
Objective: To evaluate possible associations between epidemiological and clinical data with risk of levodopa-induced dyskinesias (LID) onset in Parkinson’s disease (PD) patients. Background: LID are…Diphasic Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: diagnosis and management in clinical practice.
Objective: To describe the occurrence, diagnostic approach, clinical management and outcome of diphasic dyskinesias (Dyskinesias-Improvement-Dyskinesias, DID) in a large group of Parkinson’s Disaese (PD) patients…Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)
Objective: To compare levodopa PK, derived from ND0612 (a proprietary liquid levodopa/carbidopa formulation designed for subcutaneous (SC) administration) with Levodopa/Carbidopa Intestinal Gel (LCIG). Background: While…Central Aortic Pressure in Parkinson’s Disease and Levodopa Effect
Objective: Central aortic pressure (CAP) is the systolic blood pressure at the root of the aorta. In young people CAP is lower than the peripheral…Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion
Objective: We report the effective treatment of troublesome dyskinesias in Parkinson’s disease (PD), unresponsive to 16-hour daytime infusions, using 24-hour Levodopa/Carbidopa Intestinal Gel (LCIG). Background:…Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients
Objective: To examine the effect of levodopa-carbidopa intestinal gel (LCIG, designated carbidopa-levodopa enteral suspension in the US) treatment relative to that of optimized medical treatment…Sleep quality in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel infusion
Objective: To describe the effects of levodopa/carbidopa intestinal gel (LCIG) infusion on sleep quality in patients with advanced Parkinson's disease (PD). Background: Worsening of sleep…How Usual Is Skin Rashes During Treatment With Levodopa / Benserazide Hydrochloride?
Objective: To clarify the possible associations of levodopa / benserazidehydrochloride usage and skin rashes. Background: Levodopa/benserazide hydrochloride is one of the best dopaminergic drug used…Wearing Off Frequency in Different Hoehn-Yahr Stages in Parkinson’s Disease
Objective: To determine wearing off frequency in different stages of Parkinson’s disease (PD). Background: Levodopa is the gold standard in the symptomatic treatment of PD. The…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 70
- Next Page »